Smoldering Multiple Myeloma Prognosis

Determine risk of progression to symptomatic multiple myeloma.


Smoldering or asymptomatic multiple myeloma (SMM) is a plasma cell dyscrasia characterized by a serum monoclonal protein level of 30 g/L or more or a proportion of plasma cells in the bone marrow of 10% or more but no evidence of end-organ damage. Individuals with SMM have a high-risk of progression to future symptomatic multiple myeloma or amyloidosis. A study from the Mayo Clinic followed 276 patients with SMM over a 26-year study period to establish prognostic factors for progression. The risk of progression was not constant over time. The overall risk of progression was 10% per year for the first 5 years, approximately 3 % per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. The proportion of plasma cells in the bone marrow and the serum monoclonal protein concentration were combined to create a risk-stratification model with three distinct prognostic groups.


Kyle et al.

Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

New England Journal of Medicine 2007 June 21, 356 (25): 2582-90

The Smoldering Multiple Myeloma Prognosis calculator is created by QxMD.

Created by on 30/12/2015

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.

1. Bone Marrow Plasmacytosis?

0/2 completed